8:00 am

Registration & Networking Coffee

8:50 am Chairman’s Opening Remarks

Biomarker Targeting Through Multimodal Imaging Applications

9:00 am Building on the Key Relationship: Setting the Goals Between Industry & Academic Imaging

• Peter Choyke Program Director Molecular Imaging, NCI

9:20 am Development of Molecularly Targeted Imaging Agents to Advance Cancer Stratification & Treatment

• Gabriela Kramer-Marek Team Leader, Preclinical Molecular Imaging, Institute of Cancer Research

9:40 am Why Imaging Biomarkers Fail?

• John Waterton Professor - Translational Imaging, University of Manchester

10:10 am Pitfalls and Promises in the Development of Imaging Biomarkers for Drug Development in Oncology

• Chaitanya Divgi VP Clinical Development & CMO, Tomopath

10:30 am Interactive Panel Discussion – Developing an Imaging Biomarker Strategy

• Peter Choyke Program Director Molecular Imaging, NCI
• Gabriela Kramer-Marek Team Leader, Preclinical Molecular Imaging, Institute of Cancer Research
• John Waterton Professor - Translational Imaging, University of Manchester
• Chaitanya Divgi VP Clinical Development & CMO, Tomopath

11:00 am

Virtual Speed Networking & Refreshments

Preclinical Technical Advances Across Imaging Modalities

11:30 am Assessing the Effects of VEGF Blockade in Preclinical Tumor Models Using Non-Invasive Imaging Modalities

• Alexander Adler Scientist, Regeneron Pharmaceuticals

11:50 am Chemical Tools for Dynamic & Multicolor Optical Imaging In Vivo

• Martin J Schnermann Investigator, National Cancer Institute

12:10 pm Bridging the Preclinical-Clinical Gap

• Vaishali Shinde Associate Director - Clinical Biomarker Innovation & Development, Quantitative Translational Sciences, Takeda

12:30 pm Interactive Panel Discussion

• Alexander Adler Scientist, Regeneron Pharmaceuticals
• Vaishali Shinde Associate Director - Clinical Biomarker Innovation & Development, Quantitative Translational Sciences, Takeda
• Martin J Schnermann Investigator, National Cancer Institute

1:00 pm

Networking & Lunch Break

Advancing Imaging Strategy to Create Robust Translational Outcomes

2:00 pm Multimodal Applications to Understand the Tumor Microenvironment

• Mark Pagel Professor, Department of Cancer Systems Imaging Department of Cancer Systems Imaging, Division of Diagnostic Imaging, MD Anderson Cancer Center

2:20 pm Multimodal Imaging for Improved Drug Efficacy Understanding

• David Leung Medical Director, Oncology Imaging, Bristol-Myers Squibb

2:40 pm An AI-Powered Digital Pathology Toolbox to Advance Oncology Biomarker Development

• Cleopatra Kozlowski Senior Scientist, Genentech

3:00 pm Panel Discussion – The Future of Digital Pathology: Challenging Traditional Standard of Care Guidelines with AI Data

• Cleopatra Kozlowski Senior Scientist, Genentech
• David Leung Medical Director, Oncology Imaging, Bristol-Myers Squibb
• Mark Pagel Professor, Department of Cancer Systems Imaging Department of Cancer Systems Imaging, Division of Diagnostic Imaging, MD Anderson Cancer Center

3:30 pm

Networking Afternoon Break

Exploring Novel Modalities across Preclinical & Clinical Stages

4:00 pm Evaluating Drug Response From Data Analysis to Advance Candidate Development

• Mohan Singh Investigator: Imaging Mass Cytometry, GlaxoSmithKline

4:20 pm Multimodal Imaging for Translating Stem Cell-Based Therapy into the Clinic

• Khalid Shah Vice Chair of Research, Brigham and Women's Hospital Director, Center for Stem Cell Therapeutics and Imaging, Brigham & Women's Hospital

4:40 pm Imaging the Tumor Environment

• Mohammad Rashidian Member of the Faculty, Dana-Farber Cancer Institute

5:00 pm Roundtable Discussions

5:45 pm Chairman’s Closing Remarks & Virtual Happy Hour